Bronchoprovocation Testing in Asthma: An Update
Komber`yati P., Katial R. K., Covar R. A.
Immunology and Allergy Clinics of North America
Vol.38, Issue4, P. 545-571
Опубликовано: 2018
Тип ресурса: Обзор
DOI:10.1016/j.iac.2018.06.010
Аннотация:
Bronchial hyperresponsiveness (BHR) is defined as a heightened bronchoconstrictive response to airway stimuli. It complements the cardinal features in asthma, such as variable or reversible airflow limitation and airway inflammation. Although BHR is considered a pathophysiologic hallmark of asthma, it should be acknowledged that this property of the airway is dynamic, because its severity and even presence can vary over time with disease activity, triggers or specific exposure, and with treatment. In addition, it is important to recognize that there is a component that is not reflective of a specific disease entity. © 2018 Elsevier Inc.
Ключевые слова:
Airway inflammation; Airway remodeling; Asthma; Bronchial hyperresponsiveness; Bronchoprovocation challenges; Bronchoprovocation testing
beta 2 adrenergic receptor; colony stimulating factor; colony stimulating factor receptor; corticosteroid; fibroblast growth factor; gamma interferon; glucocorticoid receptor; granulocyte macrophage colony stimulating factor; heparin derivative; histamine; imatinib; immunoglobulin E; interleukin 10; interleukin 13; interleukin 3; interleukin 4; interleukin 5; interleukin 5 antibody; interleukin 9; mepolizumab; methacholine; montelukast; nitric oxide; omalizumab; ovalbumin; placebo; salmeterol; tezepelumab; tumor necrosis factor; unindexed drug; airway obstruction; asthma; atopy; bronchoconstriction; bronchoprovocation test; chromosome 5q; clinical feature; cytokine production; disease activity; disease severity; drug dose comparison; eosinophilia; forced expiratory volume; genetic susceptibility; genome-wide association study; human; nonhuman; pathophysiology; priority journal; provocation test; respiratory tract inflammation; Review; treatment duration; treatment outcome; asthma; bron
Язык текста: Английский
ISSN: 1557-8607
Komber`yati P. Paskuale 1988-
Katial R. K.
Covar R. A.
Комберьяти П. Паскуале 1988-
Катиал Р. К.
Cовар Р. А.
Bronchoprovocation Testing in Asthma: An Update
Текст визуальный непосредственный
Immunology and Allergy Clinics of North America
Elsevier Science Publisher B.V.
Vol.38, Issue4 P. 545-571
2018
Обзор
Airway inflammation Airway remodeling Asthma Bronchial hyperresponsiveness Bronchoprovocation challenges Bronchoprovocation testing
beta 2 adrenergic receptor colony stimulating factor colony stimulating factor receptor corticosteroid fibroblast growth factor gamma interferon glucocorticoid receptor granulocyte macrophage colony stimulating factor heparin derivative histamine imatinib immunoglobulin E interleukin 10 interleukin 13 interleukin 3 interleukin 4 interleukin 5 interleukin 5 antibody interleukin 9 mepolizumab methacholine montelukast nitric oxide omalizumab ovalbumin placebo salmeterol tezepelumab tumor necrosis factor unindexed drug airway obstruction asthma atopy bronchoconstriction bronchoprovocation test chromosome 5q clinical feature cytokine production disease activity disease severity drug dose comparison eosinophilia forced expiratory volume genetic susceptibility genome-wide association study human nonhuman pathophysiology priority journal provocation test respiratory tract inflammation Review treatment duration treatment outcome asthma bron
Bronchial hyperresponsiveness (BHR) is defined as a heightened bronchoconstrictive response to airway stimuli. It complements the cardinal features in asthma, such as variable or reversible airflow limitation and airway inflammation. Although BHR is considered a pathophysiologic hallmark of asthma, it should be acknowledged that this property of the airway is dynamic, because its severity and even presence can vary over time with disease activity, triggers or specific exposure, and with treatment. In addition, it is important to recognize that there is a component that is not reflective of a specific disease entity. © 2018 Elsevier Inc.